CTLA4 antibody (FITC)

Catalog No. ABIN161253

Product Details anti-CTLA4 Antibody (FITC)

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Reactivity: Rat

Host: Mouse

Clonality: Monoclonal

Conjugate: This CTLA4 antibody is conjugated to FITC

Application: Please inquire

Specificity: Rat CD152

Immunogen: Purified rCTLA-4hlg fusion protein . Fusion Partner: X63 Ag8.653 myeloma cells . Donor: BALB/c mice spleen cells

Clone: WKH 203

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 0.1 mg/ml

Buffer: FITC conjugated Ig buffered in PBS, 0.02% NaN and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. (Purified from ascitic fluid via Protein G Chromatography).

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Target Details for CTLA4

Target: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Alternative Name: CD152 (CTLA-4) (CTLA4 Products)

Synonyms: CTLA-4 antibody, CTLA4 antibody, CD152 antibody, Cd152 antibody, Ctla-4 antibody, Ly-56 antibody, CD antibody, CELIAC3 antibody, GRD4 antibody, GSE antibody, IDDM12 antibody, sCTLA4 antibody, cytotoxic T-lymphocyte associated protein 4 antibody, cytotoxic T-lymphocyte-associated protein 4 antibody, CTLA4 antibody, Ctla4 antibody

Background: Anti-rat CD152 monoclonal antibody is specific for the cytotoxic T lymphocyte- associated protein 4 (CTLA-4), also called CD152. This antigen is known to be the receptor for B7 ligands (CD80 and CD86) present on antigen presenting cells. A subset of CD4 T cells expressing CD25 and CTLA-4 has been recognized as a potent suppressor cell popu- lation, counteracting autoimmunity and inflammation. These `regulatory' T cells (Treg) which produce the anti-inflammatory cytokine interleukin-10 (IL-10) but not IL-2, are able to suppress the proliferation of costimulated CD25- negative indicator cells. The capacity of these naturally occurring regulatory T cells to suppress autoimmunity and inflammation suggests that therapies which activate and expand this subset could become extremely effective treatments for these immunopathological disorders. This clone has been tested in flow cytometry. In rats, the constitutive expression of CTLA-4 at the level detectable by flow cytometry is restricted to the CD25+ subset of CD4 T cells and thymocytes.

Pathways: Cancer Immune Checkpoints